Drug intelligence / Profile preview

P-010

Development stage: Preclinical
Lead developer: Pangea Pharmaceuticals
Modality: Small Molecules

Overview

P-010 is an investigational drug candidate being developed by Pangea Pharmaceuticals for the treatment of allergic conditions. Pangea Pharmaceuticals is a specialty pharmaceutical company that focuses on the development of reformulated and generic products rather than novel molecular entities. Consequently, P-010 likely represents a new formulation, dosage form, or delivery method of an existing anti-allergic agent. Specific details regarding its active pharmaceutical ingredient, molecular target, and clinical development phase are currently not publicly disclosed on the company's pipeline.

Targets

H (Histamine receptors)

Beyond the preview

Go deeper on P-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P-010.

Explore the full profile